Original Article

1

Pharmaceutical Sciences and Research (PSR), 7(1), 2020, 1 - 8

Evaluation of Potential Drug Interaction of Analgesic in Cancer
Patient Receiving Palliative Care in Dharmais Cancer Hospital
Eme Stepani Sitepu*, Atika Wahyu Puspitasari, Nuriza Ulul Azmi, Lila Nilam Sari
Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia
ABSTRACT

ARTICLE HISTORY
Received: August 2019
Revised: February 2020
Accepted : April 2020

Analgesics are mostly used in cancer patients receiving palliative care to improve the quality of life
of patients. Besides analgesics, cancer patients receiving palliative care were also given other drugs
in combination to overcome other symptoms of cancer, and this combination could potentially cause
drug interactions. This study was aimed to analyze the potential of drug interactions with analgesics
in cancer patients. The study design was cross-sectional with a retrospective method and descriptive
study. The sample of this study was cancer palliative care patient’s prescription at Dharmais Cancer
Hospital in the period of January – December 2017. The sample analyzed in this study consisted of 273
prescriptions. This study found that there were 191 prescriptions (69.9%) of analgesics which potentially interacted with 316 interaction cases. Fentanyl and morphine with 61 cases (19.3%), morphine and
gabapentin with 60 cases (18.9%) and morphine and amitriptyline with 33 cases (10.4%) were observed
as the three most analgesics-other drugs interaction. Based on severity levels, there were 73.5% of
major interaction, 26.3% of moderate interaction, and 0.2% of minor interaction. This study concluded
that high occurrence of drug interactions was observed in analgesic drugs, therefore close monitoring
is needed in cancer patient receiving palliative care.
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INTRODUCTION
Palliative care is an approach to improve the quality
of life of patients and their families in coping with
problems related to life-threatening diseases (WHO,
2014). Generally, palliative care is aimed not only
to reduce the pain and other physical symptoms, but
also to provide support psychosocially and spiritually
to patients and their families during treatment and
mourning time (Health Ministry of Indonesia, 2017).
Palliative care is given to patients with these diseases,
such as cardiovascular, cancer, chronic respiratory, HIV/
AIDS, diabetes, kidney, liver cirrhosis, tuberculosis
medicine resistant, Parkinson, arthritis rheumatoid, and
multiple sclerosis. However, the patient who needs
palliative care the most after cardiovascular patient is
cancer patient with the prevalence number of 34.01%
(WHO, 2014).
Palliative care in cancer patients is usually given to
manage symptoms like pain, psychiatric disorders,
digestive system disorders, haematology disorders, and
nervous system disorders (Health Ministry of Indonesia,
2017). The studies on breast and cervix cancer patients
showed that the most prevalence of symptom that
appeared in palliative care is a pain (93.82%). Other
symptoms are vomit (26.40%), nausea (23.03%), weight
loss (17.42%), cough (7.87%), difficulty in breathing
(7.30%), fatigue (4.49%), and lymphedema (9.55%)
(Elumelu et al., 2013).

The prevalence of pain becomes the highest in palliative
care because most cancer patients have tumours pressing
their organs, nerves, or bones that resulting in severe
ache. Moreover, the pain is also caused by chemotherapy
side effects, bad blood circulation, inflammation, and
muscle cramps (Cancer Council Australia, 2015). That
pain could be reduced by pharmacological therapy
in a long duration of time, such as the administration
of analgesic and adjuvant drugs. Besides analgesics,
palliative patients are also given other drugs to manage
other accompanying symptoms (Health Ministry of
Indonesia, 2017), and this combination of drugs can
potentially cause drug-drug interactions (Scott et al.,
2013). The study by Leeuwen (2012) showed that there
was a relationship between the numbers of drugs and the
potential interaction of cancer drugs (p<0.0001).
Dharmais Cancer Hospital (RSKD) is a national cancer
hospital and becomes the cancer reference center in
Indonesia. As the cancer reference center, RSKD is
functioned to give services, organize prevention and
early detection activities, perform researches and to
provide education (Panigoro, 2014). These functions
encourage researchers to identify the potential drug
interactions with analgesics in cancer patients receiving
palliative care in this hospital. The purpose of this
research is to analyze the types of analgesics, their
interaction with other drugs, the severity levels and the
proportion of interactions in the prescriptions of cancer
patients receiving palliative care at RSKD. This study
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Table 1. Characteristic of the study sample
Characteristic of Sample

Number

Percentage (%)

Sex
Female
Male

187
86

68.5
31.5

Age (years)
Adult (25 – 45)
Elderly (>45)

38
235

13.9
86.1

could be used as considerations in prescribing and
treating cancer patients related to the drug interactions
that occurred in cancer patients receiving palliative care
at Dharmais Cancer Hospital.
METHODS
Study Design
The study was conducted using a descriptive crosssectional design. The data were collected retrospectively
using the secondary data from the prescription forms
of cancer patients receiving palliative care at Dharmais
Cancer Hospital in 2017. This study was carried out at
RKSD in Letnan Jendral S. Parman Street Kav 84 – 86,
Slipi, Palmerah, West Jakarta. The study population is
every single one prescription forms of cancer patients
receiving palliative care at RSKD from January until
December 2017. The sample collecting technique used
was the total sampling method. The samples used were
the prescription forms of cancer patients receiving
palliative care who took combination of analgesic and
other drugs at Dharmais Cancer Hospital in 2017 who
fulfilled inclusion criteria. The inclusion criteria for
this study are cancer patients over twenty-five years old
who have prescribed two or more types of drugs, one of
which is analgesics, whereas exclusion criterion is the
patients who took chemotherapy treatments.
The study has received permitted and ethics committee
has approved (No. 036/KEPK/III/2018). The secondary
data was further collected from the prescription forms
of cancer patients receiving palliative care in 2017. The
prescription data was taken from RSKD information
system which consists of names, genders, ages, types
of drugs prescribed, and dosage information. The
analysis of the drug interactions was carried out using
Micromedex® application from Truven Health Analytic
and recent literature study manually.
RESULTS AND DISCUSSIONS
The total population of this study was 738 prescriptions,
however, only 273 prescriptions fulfilled the inclusion
criteria. The characteristics of the research sample is
shown in Table 1. A number of 68.5% of the samples
E-ISSN 2477-0612

were female patients, while 31.5% were male. The female
patients were more than male because of a distinctive
response from each gender towards pain. Females tend
to have lower pain resistance compared to males. The
pain in female patients is associated with a decrease
in estrogen levels. The estrogen levels in menopausal
woman change to a very low level causing they are more
susceptible to pain response. Hormone Replacement
Therapy (HRT) is used to manage the pain caused by the
concentration of the hormone. This condition was also
shown by the amount of sample from elderly patients
(>45 years old) which resulted in 86.1%. A bigger
number of elderly patients with palliative care than
adult patients because mostly elderly patients have more
complex problems, such as physical problems affecting
their abilities to do their daily activities independently,
and mental problems making them feel panicked of their
disease diagnosis. Therefore, the palliative care team(s)
is needed to assist elderly patients and their families
(Davies & Higginson, 2014; Pieretti et al., 2016; Vincent
& Tracey, 2008).
Prescription Pattern
The analgesics description in the pain management of
cancer patients receiving palliative care is presented
in Table 2. The pain management of cancer patients
receiving palliative care at RSKD uses the WHO Step
Ladder. The most prescribed opioid analgesic during
pain therapy was morphine (25.6%) and fentanyl
(17.3%). According to WHO Ladder, morphine and
fentanyl are given to patients with the highest pain scale
(7-10). Opioid analgesia is given to cancer patients
because 70–80% of cancer patients suffered from the
middle until high pain levels. The pain occurs because of
the effect of the tumours which press the patients’ bones,
nerves, and other body organs. Many of the international
organizations reported that by using WHO Step Ladder
properly, 90% of the pain therapy succeeded to reduce
the level of pain suffered by the cancer patients. Giving
morphine decrease the pain much better and this strong
opioid is needed to relieve the unbearable pain. However,
each patient may have different responses towards
morphine, so that to accomplish the optimum result of
analgesic effect, titration dosage of morphine is needed.
Therefore, the use of morphine needs to be evaluated
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Table 2. The analgesics description in the pain management of cancer patients receiving palliative care
Classification of Drug
Opioid Analgesic
Morphine
Fentanyl
Codeine
Tramadol
Hydromorphone
Oxycodone
Non Opioid Analgesic
Paracetamol
Ibuprofen
Ketoprofen
Aspirin
Parecoxib
Analgesic Adjuvant
Gabapentin
Amitriptyline
Hyoscine butylbromide
Valproic Acid
Pirasetam
Phenytoin
Alprazolam
Diazepam
Ibandronic Acid
Methylprednisolone
Dexamethasone
Budesonide

Number

Percentage (%)

150
101
5
3
3
1

25.6
17.3
0.8
0.5
0.5
0.2

94
18
3
1
1

16.1
3.1
0.5
0.2
0.2

94
52
17
4
8
2
3
3
2
2
15
3

16
8.9
2.9
0.7
1.4
0.3
0.5
0.5
0.3
0.3
2.6
0.5

Table 3. Percentage of potential drug interaction on prescription
Potential Interaction

Number

Percentage (%)

Interacted
Not Interacted

191
82

69.9
30.1

TOTAL

273

100

individually because each patient has a different dosage
requirement. Observing patients towards morphine
intake is performed during one until four weeks after
the chronic pain therapy or the increased dosage began.
Another type of analgesic is fentanyl. Along with the
previous research on the international journal on clinical
pharmacy, fentanyl was one of the most opioid analgesics
prescribed during pain therapy after morphine. Fentanyl
in patch form is needed by terminal cancer patients to
decrease the pain in a certain period of time (Dowell,
2016; Jain P., Pai K., & Chatterjee A., 2015; Health
Ministry of Indonesia, 2017; Masman, 2015; Rana et al.,
2011).
Meanwhile, the most prescribed nonopioid analgesic was
paracetamol with a percentage of 16.1%. It was aligned
with WHO Step Ladder guidance which explains that
paracetamol is given to the patient with the lowest pain
level (1 – 3). Paracetamol is usually preferred because

of the lowest side effects compared to NSAIDs (Health
Ministry of Indonesia, 2017; McClay, 2010).
The most commonly prescribed adjuvant drug for pain
management in cancer patients receiving palliative
care was gabapentin (16%). Gabapentin is an analgesic
acted on subunit alpha-2 δ voltage-gated calcium by
increasing GABA synthetic (gamma-aminobutyric acid)
which functioned as the neurotransmitter inhibitor on
the central nervous system. Based on the completed
case studies, adjuvant like gabapentin has been proved
to support the action of opioid analgesics on cancer
patients’ management. The other adjuvant pain drug
prescribed was amitriptyline (8.9%). It is a tricyclic
antidepressant known as a serotonin-norepinephrine
reuptake inhibitor (SNRI) which is a neurotransmitter
in pain modulation so that able to reduce the pain.
Amitriptyline has also been proven to reduce pain for
patients who suffer neuropathic pain. Gabapentin and
E-ISSN 2477-0612
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Table 4. Data of potential analgesic and drug interaction based on severity level

Drug Interaction
Major Interaction
Opioid Analgesic – Opioid Analgesic
Fentanyl – Morphine
Codeine – Fentanyl
Fentanyl – Tramadol
Hydromorphone – Morphine
Morphine – Tramadol
Opioid Analgesic – Analgesic Adjuvant
Morphine – Amitriptyline
Fentanyl – Amitriptyline
Fentanyl – Alprazolam
Morphine – Alprazolam
Fentanyl – Dexamethasone
Codeine – Dexamethasone
Opioid Analgesic – Other drugs
Morphine – Ondansetron
Fentanyl – Ondansetron
Morphine – Metoclopramide
Fentanyl – Metoclopramide
Fentanyl – Ranitidine
Tramadol – Ondansetron
Fentanyl – Ciprofloxacin
Morphine – Captopril
Tramadol – Ciprofloxacin
Hydromorphone – Metoclopramide
Morphine – Chlorpeniramine Maleate
Codeine – Ranitidine
Non Opioid Analgesic – Analgesic Adjuvant
Ibuprofen – Amitriptyline
Non Opioid Analgesic – Other drugs
Ibuprofen – Warfarin
Ibuprofen – Rivaroxaban
Analgesic Adjuvant – Analgesic Adjuvant
Diazepam – Phenytoin
Analgesic Adjuvant – Other drugs
Amitriptyline – Ondansetron
Amitriptyline – Ciprofloxacin
Amitriptyline – Chlorpeniramine Maleate
Amitriptyline – Metoclopramide
Moderate Interaction
Opioid Analgesic – Analgesic Adjuvant
Morphine – Gabapentin
Opioid Analgesic – Other drugs
Morphine – Furosemide
Non Opioid Analgesic – Other drugs
Paracetamol – Warfarin
Paracetamol – Phenytoin
Analgesic Adjuvant – Other drugs
Gabapentin – Antacid
Amitriptyline – Warfarin
Alprazolam – Omeprazole
Dexamethasone – Fluconazole
Dexamethasone – Warfarin
Dexamethasone - Aspirin
Dexamethasone – Phenytoin
Minor Interaction
Analgesic Adjuvant – Other drugs
Diazepam – Omeprazole
TOTAL

E-ISSN 2477-0612

Incidence

Percentage (%)
73.5

61
4
1
1
1

19.3
1.3
0.3
0.3
0.3

33
4
3
2
2
1

1.4
1.3
0.9
0.6
0.6
0.3

32
22
19
13
3
2
2
1
1
1
1
1

10.1
6.9
6
4.1
0.9
0.6
0.6
0.3
0.3
0.3
0.3
0.3

4

1.3

2
1

0.6
0.3

1

0.3

7
1
1
4

2.2
0.3
0.3
1.3
26.3

60

18.9

4

1.3

3
1

0.9
0.2

6
4
1
1
1
1
1

1.9
1.3
0.2
0.2
0.2
0.2
0.2
0.2

1
316

0.2
100
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amitriptyline are neuropathic analgesics prescribed
at Dharmais Cancer Hospital, so these drugs are used
as an adjuvant in the pain therapy at RSKD (Dawson,
2014; RSKD Pharmacy and Therapy Committee, 2017;
Moore, 2015; Rana, 2011; Su, 2015).

management of prescribing morphine and gabapentin at
the same time could be carried out by giving morphine
two hours before gabapentin administration so that the
lowering intestinal motility has already happened before
gabapentin is given (Chen et al., 2015).

Drug Interactions
The drug interactions from 273 prescriptions fulfilled
inclusion criteria were analyzed based on the severity
level using Micromedex Drug Interaction Checker. As
shown in Table 3, 191 out of 273 prescriptions (69.9%)
potentially had drug interactions. The analysis results of
drug interactions with an analgesic are presented in Table
4, it was found that 316 cases with the major severity
level were 73.5%, the moderate level was 26.3%, and the
minor level was 0.2%.

Morphine and amitriptyline is the opioid analgesic and
adjuvant drug. This combination has potential major
severity in drug interactions. The drug interaction effect
between morphine and amitriptyline is the increase in
serotonin syndrome risks. Morphine is the opioid type
with glucuronidase metabolism, while amitriptyline
is the tricyclic antidepressant type (TCA) which is a
noncompetitive glucuronidase inhibitor. Therefore, the
combination could inhibit the metabolism of morphine.
Based on the reports of the lung cancer patient with bone
metastasis consuming both morphine and amitriptyline,
amitriptyline was used not only to decrease incidental
pain and contribute to cause a sedative effect but
also to delay morphine clearance so that increase the
serotonergic effect. The accumulated amitriptyline
resulted from 24-hours half-life could increase the risk
of drug interaction with morphine (Upadhyay, 2008).
The administration of amitriptyline with morphine or
the same type of analgesics is carried out by giving
amitriptyline with a smaller dosage (The Christie NHS
Foundation Trust, 2012).

The drug interactions with major severity level were
mostly occurred on fentanyl and morphine combination,
resulting in 61 cases (19.3%). The interaction effects
occurring between these two drugs are increasing
respiratory depression, central nervous system, and
serotonin syndrome risks. Fentanyl and morphine have
a similar analgesic mechanism that impacts the central
nervous system and serotonin concentration so that using
these two drugs at the same time could increase the effect
or have the synergistic effect (Kotlinska-Lemieszek,
2015). Fentanyl is prescribed based on the morphine
dosage which needs time adjustment by twenty-four
hours in advance. Fentanyl and morphine could be
administered simultaneously by managing interval time
of administration and using different dosage forms. The
transdermal effect from fentanyl is reached maximally
after twelve hours of intake. If the patient is prescribed
oral morphine every four hours, it could be administered
until twelve hours after transdermal fentanyl intake.
Meanwhile, if the patient is given modified oral morphine
every twenty-four hours, transdermal fentanyl could be
given twelve hours after morphine dosage optimally
reached (Kuczynska, 2017).
Morphine and gabapentin are the combinations of opioid
and adjuvant drug which potentially cause moderate drug
interactions. The drug interaction effect of combining
morphine and gabapentin is increasing the plasma
concentration of gabapentin due to pharmacokinetic
changes. Therefore, the pharmacokinetic effect is the
increase of gabapentin absorption, which is caused by
the effect of morphine lowering the intestinal motility.
This effect leads to longer gabapentin transit time in the
intestine and resulting in the absorption of gabapentin
more than needed and increasing the plasma concentration
of gabapentin. The combination of these two drugs at the
same time could increase the level of AUC gabapentin
by 44.4% resulting in multiplying the side effects of
gabapentin (P<0.05) (Feng et al., 2017). The therapy

Furthermore, the combination of morphine and
ondansetron has a potential drug interaction with
the effect of increasing the serotonin syndrome risk.
Ondansetron is an antiemetic drug acted as a 5-HT3
receptor antagonist and associated with the serotonin
concentration inside the body. Moreover, serotonin is
known to increase the serotonergic activities, therefore,
the administration of morphine and ondansetron at the
same time could initiate the serotonin concentration to be
higher and simultaneously make the serotonin syndrome
happens. The serotonin syndrome is originated from
the hyperstimulation of the 5-HT receptor causing
mental status changes, conscious effects, autonomy
dysfunctional, and neuromuscular abnormalities
(Vizcaychipi, 2007). Therefore, monitoring the effects
of the serotonin syndrome and giving the serotonin
antagonist such as cyproheptadine and chlorpromazine
are needed during the therapy management (Vizcaychipi,
2007). On the other hand, a combination of fentanyl
and ondansetron also potentially cause major drug
interaction with a similar effect, increasing the risk of
serotonin syndrome. Ondansetron is an antiemetic with
a 5-HT3 antagonist mechanism used in the serotonin
syndrome precipitation. Fentanyl is a 5-HT1 antagonist
adding more serotonin releases by using serotonin takes
and serotonin intrasynaptic level increases. In the case
study of fifty-eight years old male patient who received
the pain therapy, he suffered from serotonin precipitation
E-ISSN 2477-0612
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Table 5. Proportion of potential analgesic and drug interactions based on gender and age

Characteristic of Patient

Sex
Age

Number of
Prescription

Prescription without
Potential Drug
Interactions

Number

Percentage
(%)

Number

Percentage
(%)

Male

66

66

24.2

20

7.3

Female

125

125

45.8

62

22.7

Adult

27

27

9.9

11

4

Elderly

164

164

60.1

71

26

imbalance that increased the possibility of serotonin
syndromes, like mental status changes, neuromuscular
abnormalities, and autonomy instabilities (Rastogi,
2011). Therefore, the above therapy management was
using nonserotonergic medicine, lowering the dosage,
stoping the administration of the serotonergic agent
(Rastogi, 2011).
Morphine and metoclopramide also potentially cause
major drug interactions. The implication caused by
these two drugs combined is the increased risk of central
nervous system depression. Morphine is the MU selective
receptor opioid with primary action in the central nervous
system in the brain. Metoclopramide is the antiemetic
medicine acted in two different mechanisms, in the
central nervous system as an antagonist on dopamine
D2 receptor and in the digestive system as a cholinergic
agonist. In the previous researches, the administration of
metoclopramide and morphine in patients undergoing
surgeries significantly shortened Tmax of morphine,
accelerated the onset, and improved the sedation, so that
it impacted the central nervous system. The increase
of morphine absorption is caused by metoclopramide
effects which increase gastric emptying (Feng, et.al.,
2017). The therapy management for this condition is
decreasing dosage to reduce the potential effects from
the administration of the gastrokinetic agent during
analgesic opioid intake simultaneously (Feng et al.,
2017).
The possibilities proportion of drug interactions with
analgesics in cancer patients could be observed based
on gender and age. Female patients’ prescriptions are
more likely to have drug interactions compared to
male patient’s prescriptions. On the other hand, elderly
patient’s prescriptions are more likely to have drug
interactions compared to adult patients prescriptions.
The data is presented in Table 5.
The gender difference between males and females is
associated with pharmacokinetic process causing the risks
to happen. During the absorption process, the absorption
E-ISSN 2477-0612

Prescription with
Potential Drug
Interactions

speed is affected by the intestine transit time. Intestine
transit time in males is lower than females and may
result in drug interactions. Besides, body fat composition
could affect the process during the distribution process.
Body fat composition in males is lower than female so
it might give an effect if the patient is prescribed with
the combination of drugs has the potential to interact.
Throughout the metabolism process, enzyme CYP3A4
and CYP2D6 activities in males are lower than females,
thus it could influence the pharmacokinetic effect of the
drug which is broken down by the enzymes (Soldin,
2009; Franconi and Campesi, 2014). Pharmacokinetic
and pharmacodynamic changes inside the body often
happen in conjunction with the aging process so the
changes are considered as the risk factors of drug
interactions. Pharmacokinetic changes happening in
geriatric patients are body composition changes, liver
function changes as a result of drug metabolism, kidney
function changes as a result of drug excretion, and
multi-pathology condition. Body composition changes
as humans grow older, the older a human becomes, the
lower body fluids get, on the contrary, the higher body
fat gains. This condition could affect the distribution of
drugs inside the body. As humans are getting aged, liver
and kidney functions are also getting lowered as the result
of the metabolism and excretion process of the drug.
Meanwhile, the pharmacodynamic changes occurred in
this process is the decrease of tissue sensitivity towards
drug as a result of degenerated drug receptor in the tissue
(Health Ministry of Indonesia, 2006; Delafuente, 2008;
Turnheim, 2003).
CONCLUSION
This study showed that the most frequently prescribed
analgesics to cancer patients receiving palliative care
at Dharmais Cancer Hospital in 2017 are morphine
(25.6%). The percentage of drug interactions towards
analgesics occurring in the prescriptions of cancer
patients with palliative care at Dharmais Cancer
Hospital in 2017 is 69.9%. fentanyl and morphine with
61 cases (19.3%), morphine and gabapentin with 60

Evaluation of Potential Drug Interaction

cases (18.9%) and morphine and amitriptyline with 33
cases (10.4%) were observed as analgesics with most
drug interaction with other drugs. The severity levels
on the drug interactions are major (73.5%), moderate
(26.3%), and minor (0.2%). Furthermore, the proportion
of analgesic drug interactions in cancer patients with
palliative care, based on gender and age category, were
found more frequently in female groups (65.4%) and the
elderly group (85.9%). Therefore for both groups, it is
recommended to prescribe alternative combinations. If
there is no alternative combination, close monitoring
should be implemented.
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